Join to access to all OVN content. Join for Free
The OVERLOOKED KOL
Advanced Practice Providers Medical Science Liaison Key Opinion Leaders Physician Assistants Nurse Practitioners

The OVERLOOKED KOL


Share This Article


Summary

In this episode, Tom Caravela hosts Leticia Price and Dawn O'Reilly to discuss the critical role of Advanced Practice Providers (APPs) in the medical field. They explore the educational backgrounds and capabilities of APPs, emphasizing their often underutilized potential as Key Opinion Leaders (KOLs). Strategies for effectively identifying and engaging APPs are shared, along with advice for Physician Assistants (PAs) and Nurse Practitioners (NPs) transitioning to Medical Science Liaison (MSL) roles. The conversation highlights the importance of networking, resource utilization, and effective time management. The episode concludes with insights into the value of APPs in medical progress and territory planning.

My guests this week are Medical Science Liaisons, Dawn O'Reilly and Letitia Price, who discuss the benefits of Medical Science Liaisons engaging with Advanced Practice Providers.

Learn more about…

πŸ‘‰ What are APPs
πŸ‘‰ Why should MSLs be calling on APPs
πŸ‘‰ How can an NP or PA transition to industry
πŸ‘‰ Why are NPs and PA’s often overlooked
πŸ‘‰ How can MSLs find success in their territory

Click for Source
Advanced Practice Providers, Medical Science Liaison, Key Opinion Leaders, Physician Assistants, Nurse Practitioners

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN